Robertson Stephens Wealth Management LLC Grows Stake in Amgen Inc. $AMGN

Key Points

• Robertson Stephens Wealth Management LLC boosted its Amgen stake by 500.2%, acquiring an additional 20,185 shares to hold 24,220 shares worth about $7.93 million at quarter-end.
• Amgen reported Q1 beat (EPS $5.15 vs. $4.77 consensus; revenue $8.62B vs. $8.58B) and set FY‑2026 guidance of $21.70–$23.10 in EPS, with analysts’ average EPS forecast near $22.16.
• Analyst views are mixed—several firms raised price targets (Goldman to $425, Argus to $400) but the MarketBeat consensus rating is "Hold" with a $357.54 target, and institutional investors own about 76.5% of the stock.

Robertson Stephens Wealth Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 500.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,220 shares of the medical research company's stock after buying an additional 20,185 shares during the quarter. Robertson Stephens Wealth Management LLC's holdings in Amgen were worth $7,928,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of AMGN. Brighton Jones LLC boosted its holdings in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC boosted its holdings in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after buying an additional 114 shares during the period. Schnieders Capital Management LLC. boosted its holdings in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock worth $7,220,000 after buying an additional 5,853 shares during the period. Main Street Financial Solutions LLC boosted its holdings in Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock worth $1,141,000 after buying an additional 416 shares during the period. Finally, Ieq Capital LLC boosted its holdings in Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock worth $15,120,000 after buying an additional 2,611 shares during the period. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMGN. Mizuho raised their price objective on shares of Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. Argus raised their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, February 6th. Barclays began coverage on shares of Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 price objective for the company. Freedom Capital downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. Finally, The Goldman Sachs Group increased their target price on shares of Amgen from $415.00 to $425.00 and gave the stock a "buy" rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Amgen has a consensus rating of "Hold" and a consensus target price of $357.54.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Stock Performance

Amgen stock opened at $329.82 on Friday. The firm's fifty day moving average price is $358.07 and its 200-day moving average price is $340.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a market cap of $178.00 billion, a P/E ratio of 23.18, a price-to-earnings-growth ratio of 3.42 and a beta of 0.47. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts expect that Amgen Inc. will post 22.16 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is presently 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.